<DOC>
	<DOCNO>NCT00973752</DOCNO>
	<brief_summary>The purpose study determine safety effectiveness multi-drug regimen ( include prednisone , vincristine , cytarabine , doxorubicin , 6 mercaptopurine , methotrexate ) consider standard treatment child young adult acute lymphoblastic leukemia ( ALL ) , combination PEG-asparaginase clofarabine treat old adult ALL . PEG-asparaginase use chemotherapy treatment regimens child adult ALL . Clofarabine use chemotherapy treatment regimens child ALL show decrease number leukemia cell . Participants leukemia abnormal chromosome , call Philadelphia chromosome , also give imatinib .</brief_summary>
	<brief_title>Treatment Older Adults With Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>- This research study stag treatment follow : 1 ) Induction 2 ) Consolidation 1 3 ) Stem cell Bone Marrow Transplant ( participant eligible ) . If participant transplant : 4 ) CNS Therapy 5 ) Consolidation 2 6 ) Continuation Therapy . - During phase study treatment , participant additional test procedure monitor health research purpose . These test include : physical exam , blood test , bone marrow aspirate/biopsy EKGs ( electrocardiogram ) and/or ECHOs ( echo-cardiogram ) . - INDUCTION STAGE : This stage last one month . The study drug way administer follow : Prednisone orally day 1-21 participant less 60 day 1-7 participant 60 great ; Vincristine intravenously day 1 , 8 , 15 22 ; Doxorubicin intravenously day 1 2 ; PEG-Asparaginase intravenously day 7 21 ; Cytarabine intrathecally day 1 ; Methotrexate intrathecally day 29 ; Imatinib orally day 14-29 participant Philadelphia Chromosome . - After induction , evidence ALL spinal fluid , participant may need receive intrathecal therapy . - CONSOLIDATION 1 Therapy : This stage last one month . Participants receive Consolidation 1 Therapy , regardless whether ALL full remission Induction . The study drug way administer follow : Prednisone orally day 1-5 ; Clofarabine intravenously day 1-5 ; PEG-Asparaginase intravenously day 1 15 ; Imatinib continue orally participant Philadelphia Chromosome . - After participant blood count return normal , bone marrow test . If bone marrow show remission , participant proceed next stage study . If bone marrow show remission , participant longer continue study . - STEM CELL BONE MARROW TRANSPLANTATION : The next stage stem cell bone marrow transplantation participant eligible . If participant receives stem cell transplant , receive additional chemotherapy ( separate study drug ) follow infusion stem cell . If participant receive bone marrow transplant , bone marrow aspirate biopsy 3 month transplant 12 month start fo induction monitor status ALL . If participant receive bone marrow stem cell transplant , continue part study , proceed CNS Therapy , Consolidation 2 Therapy , Continuation Therapy . - CENTRAL NERVOUS SYSTEM ( CNS ) THERAPY : CNS therapy begin 2 6 week follow end Consolidation 1 . This stage last one month . The study drug way administer follow : vincristine intravenously day 1 ; doxorubicin intravenously day 1 ; 6 mercaptopurine orally day 1-14 ; prednisone orally day 1-5 ; PEG-asparaginase intravenously day 1 15 ; methotrexate/cytarabine/prednisone intrathecally weekly 3 week ; imatinib orally continue daily participant Philadelphia Chromosome . - Radiation therapy also give stage participant 60 year old . The purpose radiation therapy prevent ALL come back brain . Radiation give 8 treatment , give day , schedule study treatment . - CONSOLIDATION 2 THERAPY : This stage begin soon CNS Therapy end last 8 month . Participants receive repeat cycle study drug treatment every 4 week . The study drug way administer follow : vincristine intravenously day 1 ; doxorubicin intravenously day 1 ; 6 mercaptopurine orally day 1-14 ; prednisone orally day 1-5 ; PEG-asparaginase orally day 1 15 ( first cycle ) ; imatinib orally continue daily participant Philadelphia chromosome . - CONTINUATION THERAPY : This stage begin end Consolidation 2 Therapy . The goal stage get rid ALL body . Participants receive repeat cycle study drug treatment every 4 week . It last participant remission 2 year . The study drug way administer follow : vincristine intravenously day 1 ; mercaptopurine orally day 1-14 ; prednisone orally day 1-5 ; methotrexate intravenously day 15 ; imatinib orally continue daily participant Philadelphia chromosome .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Acute lymphoblastic leukemia , exclude know mature Bcell ALL presence follow : surface immunoglobulin , L3 morphology , ( 8 ; 14 ) ( q24 ; q32 ) , ( 8 ; 22 ) , ( 2 ; 8 ) . Patients mature Bcell ALL remove protocol soon diagnosis make treat Bcell leukemia protocol . Patients lymphoblastic lymphoma also eligible No prior antileukemic therapy except &lt; 1 week steroid , and/or emergent radiation therapy mediastinum , hydroxyurea emergent leukopheresis . Longer steroid use disease leukemia permit . Age 5175 year Ejection fraction &gt; 45 % Creatinine &lt; 2.0 mg/dl Total bilirubin &lt; 3.0 mg/dl ECOG ( Eastern Cooperative Oncology Group ) Performance Status 0 , 1 , 2 Nonpregnant non lactate Known HIV positive Comorbid medical condition , investigator 's opinion , would make participation trial adherence protocol guideline difficult Active psychiatric mental illness making informed consent careful clinical followup unlikely</criteria>
	<gender>All</gender>
	<minimum_age>51 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>ALL</keyword>
</DOC>